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4 primarily suppresses MT dynamics without significantly affecting the MT-polymer mass [3, 4] . 72 PTX is one of the most successful chemotherapeutic drugs in history. It is currently used to 73 treat patients with a variety of cancers including lung, breast and ovarian cancers [5] . 74 Several mechanisms have been proposed to explain the anti-tumor activity of PTX. It can 75 induce a mitosis dependent cell death, either by producing a mitotic arrest [6] , when applied 76 at high concentrations, or by promoting chromosome mis-segregation at low concentrations 77 [7] . Alternatively, PTX can act on interphase cells and drive autonomous cell death by 78 perturbation of intracellular trafficking [8] . It has also been recently proposed that post-79 mitotic formation of micronuclei induced by PTX can promote inflammation and subsequent 80 tumor regression via vascular disruption and immune activation [9] . 81
While PTX is a successful anti-cancer drug, its low solubility, its toxicity, and the fact that 82 cells become resistant to this drug, impose serious limits to its use. Cell resistance to PTX is 83 due to the high expression of P-glycoprotein or multidrug resistance-associated proteins, as 84 well as to the overexpression of some -tubulin isoforms or mutations in -tubulin that affect 85 the MT polymer mass and/or drug binding [10] . Another major drawback of PTX in clinical 86 applications is the development of peripheral neuropathies, primarily involving the sensory 87 nervous system. Although the molecular bases of these neuropathies are not completely 88 understood, an inhibition of MT-based axonal transport appears to be a possible mechanism 89
[11]. It has been recently shown that anterograde kinesin based-axonal transport is 90 specifically affected by PTX, whereas MT destabilizing drugs that bind preferentially to the 91 ends of MTs have much less effect on axonal transport [12] . 92
An alternative therapeutic solution would be the use of pharmaceutics which, when co-93 administrated with PTX, could potentiate its effect without significantly increasing its toxicity. 94
Such agents could allow the use of lower doses of PTX in cancer therapy, may limit the 95 occurrence of resistances and reduce MT-independent adverse effects. 96 5 To identify such agents, we have screened a collection of 8,000 original compounds using a 97 cytotoxicity assay and selected a derivative of the carbazolone series (Carba1) able to 98 sensitize cells to a low, non-toxic dose of PTX. We demonstrated that Carba1 exerts 99 synergistic cytotoxic effects with PTX. In cells, Carba1 has no major effect on the total MT 100 mass in interphase cells and shows moderate cytotoxicity. We found that Carba1 targets the 101 colchicine binding-site of tubulin and inhibits in vitro tubulin polymerization. Carba1-induced 102 modulation of MT dynamics increases the accumulation of fluorescent PTX (Fchitax-3) 103
inside MTs, providing a structural explanation of the observed synergy between Carba1 and 104 PTX in cells. 105
Carba1 has no major anti-tumor effect when administrated alone in animals and no detectable 106 toxicity. The administration of a combination of Carba1 and a low, ineffective, dose of PTX 107 showed, however, a significant effect on tumor growth, indicating that Carba1 and PTX act 108 synergistically in vivo. Our results pave the way for new therapeutic strategies, based on the 109 combination of low doses of MT targeting agents with opposite mechanisms of action. These 110 combinations may have reduced toxicity compared to high therapeutic PTX doses. 111 112 113
Results 114
A pairwise chemical genetic screen identifies a carbazolone derivative, Carba1, that 115 sensitizes cells to paclitaxel 116
We designed a screen to select compounds that sensitize cells to paclitaxel (PTX). In a first 117 step, we determined a minimal dose of PTX that is not toxic for cells. We found that 1 nM of 118 PTX showed no toxicity when applied on HeLa cells for 48 hours ( Supplementary Fig 1) . 119 Furthermore, such a dose has no detectable impact on MT dynamics as assessed by EB3 120 tracking after time lapse fluorescence microscopy using GFP-EB3-transfected HeLa cells and 121 6 subsequent calculation of dynamic instability parameters ( Supplementary Table 1 ). 122
We then screened a library of 8,000 compounds at a concentration of 5 µM (Fig 1A and  123 Supplementary Table 2 ) and compared their cytotoxicity on HeLa cells when administrated 124 alone or in combination with 1 nM PTX. We selected 76 compounds that show no or 125 moderate cytotoxicity when applied alone, and that were found cytotoxic when applied in 126 combination with 1 nM PTX. We decided to focus our study on the 6-chloro-1,4-dimethyl-3-127 pyrrol-1-yl-9H-carbazole (Carba1, Fig 1B) because it did not display reactive chemical 128 groups that could interact not specifically with protein targets and because it showed a 129 synergistic activity with PTX ( Fig 1C) . Indeed, the comparison of HeLa cell apoptosis 130 induced by Carba1 (12 M), PTX (1 nM) to the apoptosis induced by the combination of 131 Carba1 and PTX (12 M/ 1 nM) confirmed the synergistic activity (Fig 1D) . 132 133 Carba1 has a moderate cytotoxicity when applied at high concentrations 134
As our final aim was to test the therapeutic efficacy of Carba1 in combination with PTX, it 135 was important to investigate its cellular effects and to check that this compound is not or 136 moderately toxic by itself. We first analyzed the cytotoxicity of Carba1 on HeLa cells, using 137 the sensitive PrestoBlue assay. As shown in Fig 2A, Carba1 has a moderate cytotoxicity with 138 a calculated GI50 of 21.8 μM after a 72-hour treatment. 139
Since the Prestoblue assay is a metabolic test that indirectly measures cell viability, we 140 directly detected cells in apoptosis using Annexin V staining, and quantified them by flow 141 cytometry. We compared the effect of two concentrations of Carba1: a concentration (12 M) 142 that has no detectable effect on cell viability and a cytotoxic concentration (25 M). No 143 apoptosis was detected when Carba1 was applied for 72 hours at a concentration of 12 M 144 whereas at 25 µM, it induced apoptosis of 30% of the cells (Fig 2B and 2C) . 145
These results indicate that Carba1 is only weakly toxic, even when applied at a high 146 7 concentration. A toxicity analysis of a single 10 M dose of Carba1 on a set of 60 human 147 cancer cell lines (NCI-60 screen [20]) confirmed the low cytotoxic activity of Carba1 148 ( Supplementary Table 3 ). 149 150 Cell-cycle progression is blocked at mitosis by Carba1 151 A videomicroscopy analysis, using different doses of Carba1, showed that the compound 152 impacted mitosis. As compared to DMSO, Carba1 (12 μM) induced a significant delay in the 153 completion of metaphase and a slight increase of aberrant mitosis (Fig 3A, B , 154 Supplementary Table 4 ). When Carba1 was applied at a 155 concentration of 25 μM, the majority of the cells stayed blocked in prometaphase (Fig 3A, B  156 and Supplementary Movie 1, right). We followed and quantified the fate of the cells treated 157 with 25 M Carba1 in a 20-hour time lapse video (Supplementary Movie 2) and noted that 158 61% of the mitotic cells eventually died during mitosis, 29% were still dividing abnormally, 159 whereas only 10% underwent apparently normal mitosis ( Supplementary Table 4 ). We thus 160 concluded that a cytotoxic dose of Carba1 induced a very long duration of mitotic arrest, 161 followed by mitotic catastrophe. 162
Supplementary Movie 1 and
In accordance with the effect of Carba1 on mitosis, a flow cytometry analysis using 163 propidium iodide staining indicated that a 15-hour exposure to 25 M Carba1 induced a dose-164 dependent cell-cycle arrest at the G2/M phase (Fig 4A) . Prolonged exposure (24 and 48 165 hours) led to a reduction of the number of cells blocked in the G2/M phase and to an increase 166 of aneuploid cells, as assessed by the increased number of cells in sub G1 and of cells 167 containing more than 4N DNA (Fig 4A) . In an attempt to understand the Carba1 mechanism of action, we first analyzed its effect on 196 cellular MTs, using immunofluorescence. Carba1 treatment (12-25 M) did not visibly 197 perturb the MT network in interphase cells, as compared to DMSO (control; Fig 5A) . In 198 mitosis, chromosome congression defects were visible in several mitotic cells of the 12 M 199 treated cell population. The occurrence of such defects was increased at a higher dose (25 200 M) of Carba1 (Fig 5A) . Such defects in chromosome congression are similar to those 201 observed on cells treated by some inhibitors of kinases involved in the mitotic process such as 202 Aurora B or Plk1 kinases [21] . Moreover, compounds structurally related to Carba1 often 203 target protein kinases [22, 23] . We therefore tested the ability of Carba1 to inhibit the activity 204 of a panel of 64 protein kinases including kinases known to be involved in the regulation of 205 the cytoskeleton and/or the cell cycle. We found that, when in vitro assayed at a 10 M 206 concentration, Carba1 did not show any selective inhibitory activity on the kinases tested 207
( Supplementary Table 5 ). It is therefore unlikely that Carba1 is a direct inhibitor of these 208
kinases. 209
The observed effects of Carba1 on the cellular MT network were reminiscent to those 210 described for low doses of MT depolymerizing agents such as nocodazole or vinca alkaloids: 211 a mitotic arrest with a similar aberrant chromosome organization, with no detectable effect on 212 the total MT mass [24] . We thus wondered if Carba1 was, as nocodazole, able to directly 213 impact MT assembly. The effect of a high dose (25 M) of Carba1 on MT dynamic instability 214 parameters was measured using time-lapse fluorescence microscopy on GFP-EB3 transfected 215 cells ( Supplementary Table 1 ). Carba1 reduced the MT growth rate as well as the MT 216 growth length, as indicated by the increase of the distance-based catastrophe frequency, and 217 increased time spent in pause, indicating that Carba1 suppresses MT dynamics. 218 10 We therefore tested the Carba1 effect on in vitro tubulin assembly. As shown in Fig 5B,  219 Carba1 was able to inhibit polymerization of pure tubulin in a dose-dependent manner. 220
Increasing Carba1 doses induced a decrease in the rate of polymerization, as well as a delay in 221 nucleation and a reduction in the total quantity of assembled MTs, attested by the scaling 222 down of the level of assembly at equilibrium (Fig 5B) . The concentration of Carba1, which 223 inhibits 50% of tubulin (30 M) assembly under these experimental conditions, was 6.9 M. 224
To assay the effects of Carba1 on MT dynamics more accurately, we assembled fluorescently 225 labeled, dynamic MTs in vitro and used total internal reflection fluorescence (TIRF) 226 microscopy to track individual MTs (Fig 5C) . We found that 4 μM Carba1 had no effect on 227 either MT catastrophe (switch from growth to shrinkage) or rescue (switch from shrinkage to 228 growth) frequencies, but induced a significant reduction in MT growth rates. Moreover, the 229 time spent inactive before a new polymerization was largely increased for Carba1 treated 230
MTs ( Supplementary Table 6 ). 231
We then looked for the binding site of Carba1 on tubulin. Among the four binding sites 232 described for MT depolymerizing agents, the most common binding site is the colchicine site 233
[1]. We checked whether Carba1 can compete with [ 3 H]-colchicine for its tubulin binding-site 234 (Fig 5D) . Carba1 selectively inhibited colchicine binding to tubulin, indicating that it binds to 235 tubulin at or near the colchicine site. However, it did not completely prevent the binding of 236 [ 3 H]-colchicine, suggesting that its affinity for this site is lower than that of colchicine. 237
In order to measure the binding constant of the compounds, a competition assay with 2-238 methoxy-5-(2,3,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one (MTC), an analogue of 239 colchicine lacking the B ring that rapidly reaches an equilibrium (Kb= 4.7x10 5 M -1 , 25ºC 240
[25]) in its binding reaction with tubulin, was designed. In the absence of tubulin the 241 compound lacked fluorescence (Fig 5E) while in the presence of tubulin an emission maxima 242 at 423 nm was observed upon excitation at 350 nm. As expected from its activity as an 243 inhibitor of [ 3 H]-colchicine binding to tubulin, Carba1 is able to displace MTC from the 244 colchicine site, strongly supporting that Carba1 binds to the colchicine site of tubulin. The 245 dissociation constant of Carba1, for the colchicine site is 3.03 ± 0.5 x10 -6 mol L-1 (Fig 5F) . 246
Altogether, these results show that Carba1 is a direct inhibitor of MT polymerization. 247 248
Carba1 binding to tubulin enhances the tubulin binding capacity of PTX and its MT 249 stabilizing activity 250
Carba1 is thus a compound that binds tubulin and impairs MT polymerization. We wondered 251 how such a mechanism of action could explain the synergy between Carba1 and PTX, a MT 252 stabilizing compound. 253
Using a fluorescent taxane analog combined with high resolution imaging of MT dynamics, it 254 has recently been shown by Rai and coll. [26] , that low non-saturating concentrations of a MT 255 depolymerizing agent such as vinblastine, enhance catastrophes and induce a modulation of 256 MT dynamics that favors an accumulation of PTX inside the MT. Such a mechanism could 257 explain the observed synergy between Carba1 and PTX. To test if the same molecular 258 mechanism is at work with Carba1, we first determined the Carba1 concentration able to 259 induce catastrophes. We found that 10 M Carba1 was able to induce a two-fold increase of 260 the catastrophe frequency, which increased further to three-fold when combined with 100 nM 261 PTX (Fig 5G, Supplementary Fig 2A, B, C) . Further, Carba1 also increased the 262 incorporation of a fluorescent derivative of PTX (Fchitax-3) within the MT shaft (Fig 5H, I) . 263 Such a result strongly suggests that the underlying mechanism for the observed synergy is that 264 Carba1 binding to MTs induces a modification of the MT lattice leading to enhanced 265 accumulation of PTX. 266 267
Carba1 and PTX act synergistically to reduce tumor growth in vivo 268
Could the synergy between Carba1 and PTX, which we observed both at the molecular and 269 the cellular levels, be translated into a therapeutic anti-cancer effect? To address this question, 270 we compared the effects on tumor growth of Carba1 and PTX administrated separately to the 271 effect of administration of Carba1 in combination with PTX, in a tumor mouse model. In a 272 first series of experiments, we analyzed the effect of increasing doses of PTX or Carba1 when 273 administered alone. To that aim, mice bearing sizable tumors, formed of HeLa cells that have 274 been xenografted, received intravenous (i.v.) injections of PTX (from 2 to 8 mg/kg), every 275 two days during 10 days (Fig 6A) . In the same experiment, we analyzed the effect of Carba1 276 (from 15 to 60 mg/kg, i.v.) injected with the same schedule (Fig 6B) . We found that PTX, 277 when administered at 4 and 8 mg/kg, induced an important reduction of tumor size (Fig 6A) . 278
Carba1 did not induce a significant effect on tumor size whatever the dose injected, although 279 a tendency towards smaller tumors appears with increasing Carba1 concentrations (Fig 6B) . We then conducted a study of the effect on tumor size of a low PTX dose (3 mg/kg) in 286 combination with Carba1 (60 mg/kg). No modification of body weight was observed 287 throughout the study, suggesting that the combination is well tolerated (Supplementary Fig  288   4 ). In this experiment PTX (3 mg/kg) has no effect on tumor size (Fig 6C) . Compared to the 289 previous experiment (no effect at 2 mg/kg, significant effect at 4 mg/kg), an intermediate Our initial aim was to discover an agent that would allow lowering the dose of PTX while 300 obtaining the same anti-tumor efficacy as the currently used therapeutic dose of PTX resulting 301 in less toxicity. We thus screened a chemical library to detect compounds able to sensitize 302 cells to a low, non-toxic dose of PTX. The test we used was a cytotoxicity test, therefore 303 probing all vital cell functions. Whereas such a whole cell-based assay screens molecules 304 having multiple potential targets and allows the biology to dictate the best targets [27], it may 305 not be insignificant to have selected Carba1, an agent that targets tubulin and impairs MT 306 dynamics. Indeed, this indicates that the most sensible target, in this specific context, is 307 tubulin. 308
Recently, a series of carbazole-based MT targeting agents with anti-tumor properties has been 309 reported, confirming the ability of this type of chemical scaffold to interact with the 310 colchicine site of tubulin [28] . The Carba1 scaffold is a versatile one and we are currently 311 synthesizing modified analogs for medicinal chemistry optimization. 312
The PTX binding site at the interior of the MT has been characterized at the atomic level: 313 PTX binds to a pocket in -tubulin that faces the MT lumen and is near the lateral interface 314 between protofilaments (for review see . This allosteric mechanism would strengthen the longitudinal tubulin contacts 318 leading to a stabilization of the MTs [1]. In this context, it is conceptually counterintuitive 319 that an agent that depolymerizes MTs acts in synergy with PTX, an agent that stabilizes them. 320
A possibility is that the binding of Carba1 to the tubulin dimer modifies its affinity for PTX. 321
However, although it has been shown that the covalent occupancy of the taxane site can affect 322 the structure of the colchicine site [31], the reverse has not yet been described. Moreover, in 323 cells, due to the low affinity of Carba1 for tubulin and the nanomolar concentration of PTX 324 that was used, it can be assumed that the probability that a single tubulin dimer has both a 325 molecule of Carba1 and another of PTX bound is very low. Thus an allosteric effect at the 326 level of the tubulin dimer, due to such a simultaneous binding, cannot be responsible for 327 synergistic cytotoxicity. 328
Another possibility is that the binding of Carba1 can induce conformational changes of the 329 growing MT ends that can facilitate the subsequent binding of PTX to the MT lattice. 330
Recently, using TIRF analysis, it has been shown that inhibition of polymerization due to 331 non-saturating doses of vinblastine induces a switch to catastrophes, which converts the MT 332 plus end to a state that allows more accumulation of fluorescent PTX, indicating a higher 333 affinity of MT growing ends for PTX [26] . Indeed, we have conducted the same type of 334 experiment, replacing vinblastine with Carba1 and observed an increase in the rate of 335 catastrophes associated with a greater incorporation of fluorescent PTX. Although the 336 underlying structural mechanism is yet unknown, it is highly probable that Carba1 acts 337 similarly to vinblastine to facilitate PTX accumulation. 338
It is known that PTX accumulates intracellularly [4], reaching intra-tumor concentrations that 339 are higher in the tumors than in the plasma [7] . It is thus remarkable that the synergistic effect 340 is observed not only at the MT level, but also at the cellular level, as well as when both drugs 341 are applied systemically in animals to exert their anti-tumor action. Although it cannot be 342 excluded that Carba1 has other targets, it is highly probable that the same mechanism is at 343 work in these different contexts. 344
Because the combined administration of Carba1 and a low dose of PTX can have an anti-345 tumor effect equivalent to the administration of high doses of PTX alone, one could imagine 346 that the combination should reduce the unwanted side effects of PTX. This has to be tested. 347
For instance the effect of the combination should be compared to the PTX effect on the 348 kinesin-based anterograde transport, since perturbation upon PTX treatment is thought to be 349 part of the mechanism involved in peripheral neuropathy. But, given the mode of action we 350 have described, with Carba1 facilitating the accumulation of PTX in MTs, we can bet that the 351 combination should diminish MT-independent adverse events. Bovine Serum, and maintained in a humid incubator at 37°C in 5% CO 2 . 372
Analysis of cell viability using MTT (screening of the chemical library) 373
The assay was performed in 96-well microplates. Cells were seeded at a density of 2,500 cells 374 per well and allowed to adhere for 24 hours before being treated for 48 hours with either 375 DMSO (0.1 % final concentration) or compounds at 5 M, with or without 1 nM PTX. 376
Viability was evaluated with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 377 (MTT) colorimetric assay (Sigma, #M5655). 378
Analysis of cell viability using Prestoblue assay 379
Cell viability was analyzed using the colorimetric Prestoblue assay (Invitrogen, #A13262). 380
Cells were seeded in 96-well microplates (Greiner, #655077) at a density of 2,500 cells per 381 well and allowed to adhere for 24 hours before being treated for 72 hours with either DMSO 382 (0.1 % final concentration) or drugs at indicated concentrations. After a 72-hour treatment, 11 383 µL Prestoblue was added to each well and cells were incubated for another 45 minutes. The 384 absorbance of each well was measured using a FLUOstar Optima microplate reader 385 (Excitation, 544 nm; Emission, 580 nm). 386
Apoptosis assay 387
The apoptosis assay was performed with FITC Annexin V Apoptosis Detection Kit I (BD 388 Biosciences, #556547) using flow cytometry and analyzed by FCS express software. 389
Cell cycle analysis 390
Cells were harvested and washed by centrifugation in PBS. Then, 10 5 cells were fixed in 1 391 mL of 70% ethanol at 4°C overnight. Following two washes with PBS the cells were 392 incubated with 50 µg/mL propidium iodide and 0.2 mg/mL RNase A (Sigma, #10109142001) 393 / PBS for 30 minutes at 37°C before analysis. The percentage of cells in the specific cell-cycle 394 phases (G0, G1, S, G2, and M) was determined using an Accuri C6 flow cytometer (Becton 395 Dickinson). 396
Immunofluorescence microscopy and live cell imaging 397
HeLa cells at a density of 20,000 cells were grown for 48 hours on glass coverslips placed in 398 a 24-well microplate. When cells reached 70% confluence the medium was replaced with a 399 fresh one supplemented with Carba1. After a 5-hour exposure to Carba1, cells were fixed and 400 permeabilized with -20°C absolute methanol for 6 minutes. After washing and saturation with 401 tubulin and H2B-mcherry were seeded on 2-well glass-slides (Ibidi, #80297) at a density of 411 7,000 cells per well and allowed to grow for 24 hours prior to imaging. After treatment, the 412 slide was placed on a 37°C heated stage, at 5% CO 2 , and images were acquired every 2.5 413 minutes by a spinning disk confocal laser microscope (Andromeda iMIC) equipped with a 414
Plan-Apochromat 20×/0.75 WD610 objective and an EMCCD camera (iXon 897). For each 415 time point, a stack of 7 planes (thickness: 1 µm) was recorded. Acquisition (LA), off-line 416 analysis (OA) and Fiji software programs were used. 417
Transfection of GFP-EB3 418
To label MT plus ends, GFP-EB3 plasmids were used because EB3 has a strong binding 419 affinity to MT plus ends. Cell transfection was performed using electroporation (AMAXA®, 420
Köln, Germany). 2 µg of purified plasmid DNA were used for each transfection reaction. 421 
Dynamic instability parameter analysis 430
The dynamic instability parameter analysis was performed by tracking MT plus ends over 431 time using the imageJ software. The methods of calculation were as described in Honoré et al. 432 [14] . 433
Tubulin Polymerization Assay 434
Tubulin was prepared from bovine brain as previously described [15] . Tubulin polymerization 435 assays were carried out at 37°C in BRB80 buffer (80 mM Pipes, 0.5 mM MgCl 2 , 2 mM 436 EGTA, 0.1 mM EDTA, pH 6.8 with KOH) by mixing 7 µM of pure tubulin, 1 mM GTP, 5 437 mM MgCl 2, and indicated concentrations of drugs (0.2% DMSO, final concentration) in a 438 final volume of 100 µL. The time course of the self-assembly activity of tubulin was 439 monitored as turbidity at 350 nm, 37°C, during 30 minutes, using a spectrophotometer 440 (ThermoScientific, Evolution 201). 441
[ 3 H]-Colchicine Tubulin-Binding Assay 442
The tubulin was prepared from bovine brain as previously described In a first series of experiment, the effects of PTX or Carba1 when administrated alone were 493 evaluated. To that aim anesthetized (4% isoflurane/air for anesthesia induction and 1.5% 494 thereafter) five-week-old female NMRI nude mice (Janvier Labs, Le Genest-Saint Isle, 495
France) were injected subcutaneously in the flank with 10 7 exponentially dividing Hela cells 496 in 1X PBS. Tumor size was measured three times a week using a caliper, and the tumor 497 volume was calculated as follows: length x (width) 2 x 0.4. When tumors have reached a 498 volume of about 200 mm 3 i.e. nine days after cell injection, mice were randomized in 7 499 groups of 6 mice each and drugs were injected intravenously every two days. A first group 500 received the vehicle (14% DMSO, 14% Tween 80 and 72% PBS). Three groups received 501 PTX at different doses (2, 4 and 8 mg/kg) while three other groups received Carba1 at 502 different doses (15, 30 and 60 mg/kg). 503
In a second series of experiments, the effect of a combination of PTX-Carba1 was evaluated, 504 and compared to the effect of the compounds alone. To that aim, five-week-old female NMRI 505 nude mice were injected subcutaneously with 10 7 exponentially dividing HeLa cells into the 506 right flank. When tumors have reached a volume of about 200 mm 3 i.e. nine days after cell 507 injection, mice were randomized in 4 groups of 8 mice each and drugs were injected 508 intravenously every two days. The first group received PTX at 3 mg/kg, the second group 509 22 Carba1 at 60 mg/kg, the third group received a combination of Carba1 (60 mg/kg) and PTX 510 (3 mg/kg), and the fourth group received the vehicle (14% DMSO, 14% Tween 80 and 72% 511 PBS). Groups were statistically compared using ANOVA. Paclitaxel (Taxol®) is a drug that has been proven in cancer chemotherapy. However, its 541 administration poses problems of toxicity, undesirable side effects and resistance. 542
To overcome this problem, rather than looking for new drugs with the same mechanism of 543 action as paclitaxel, but less toxic, we looked for drugs that work synergistically with 544 paclitaxel to kill cancer cells, by screening a large chemical library. The underlying idea was 545 to find a way to achieve the same therapeutic efficacy, but with lower doses of paclitaxel. 546
RESULTS 547
We describe a compound that acts synergistically with paclitaxel. This compound acts using a 548 recently described mechanism: it modulates the dynamics of the end of the microtubules, 549 facilitating the accumulation of paclitaxel inside the microtubule. This action at the 550 microtubule level results in reduced tumor growth in an animal model. Thus, the same 551 effectiveness as a therapeutic dose of paclitaxel is obtained when a lower dose of paclitaxel is 552 used in combination with the compound. 553
IMPACT 554
The presented results pave the way for new therapeutic strategies, based on the combination 555 of low doses of microtubule targeting agents with opposite mechanisms of action. (1 nM) alone has no effect on cell viability, compounds (5 M) that have no effect when 661 applied alone but induced cell death when applied in combination with PTX (1 nM) were 662 
